The US Food and Drug Administration (FDA) has approved daprodustat (Jesduvroq), the first oral treatment for anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for ...

The FDA has approved daprodustat (Jesduvroq, GSK) for the once daily treatment of anemia caused by chronic kidney disease (CKD) in adults administered dialysis for at least 4 months. 1 The oral ...

The FDA has approved daprodustat, the first oral treatment for anemia for adults receiving dialysis for at least 4 months. Daprodustat is the first hypoxia-inducible factor prolyl hydroxylase ...

Jesduvroq (daprodustat) approved by US FDA for anemia of chronic kidney disease in adults on dialysis. News release. GSK plc. February 1, 2023. Accessed February 2, 2023.

The Food and Drug Administration has approved Jesduvroq tablets (daprodustat), the first oral treatment for renal disease-related anemia in adults who have been on dialysis for four months or more ...

The FDA is due to make an approval decision on GSK's drug by Feb. 1, 2023. Outside the U.S., daprodustat is also in the running for marketing authorization in Europe.

Roxadustat failed FDA approval due to issues with seizures, infections and thromboembolic disease (including VAT in patients on dialysis) that were not seen with daprodustat. Vadadustat failed FDA ...

The FDA has approved Jesduvroq tablets for treatment of anemia in patients with chronic kidney disease who are on dialysis, according to a press release.The agency qualified the approval by ...

If the FDA is happy with daprodustat's safety profile and approves the drug, it will help GSK meet its target of £500 million to £1 billion ($650 million to $1.3 billion) in sales for the drug ...

(RTTNews) - The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been ...

Daprodustat is vying to become the first drug in the HIF-PHI inhibitor class to reach the US market, after the FDA rejected two others – FibroGen/AstraZeneca's roxadustat and Akebia's vadadustat ...

· Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of chronic kidney disease a new oral treatment option Tony Wood, President and Chief Scientific ...